Hematopoietic stem cell mobilization in relapsed or refractory lymphomas: A multi-center experience with BEGEV± rituximab.
文献摘要
Background BEGEV (bendamustine, gemcitabine, vinorelbine, and prednisolone) is an established salvage regimen for relapsed/refractory Hodgkin lymphoma (HL), and previous studies have reported favorable stem cell mobilization outcomes. Most of these data, however, come from classical HL, while detailed experience in non-Hodgkin lymphoma (NHL) and mixed lymphoma cohorts remains limited. Methods We retrospectively evaluated 31 adults with HL or NHL who underwent BEGEV-based peripheral blood stem cell mobilization at multiple centers. The analysis included mobilization kinetics, peripheral blood and collected CD34 + cell counts, number of apheresis procedures, plerixafor use, hematologic toxicity, subsequent autologous stem cell transplantation (ASCT), and post-transplant engraftment. Successful mobilization was defined as collection of at least 2 × 10 6 CD34 + cells/kg. Results Of the 31 patients, 20 (64.5%) had HL and 11 (35.5%) had NHL. Thirteen (41.9%) had thrombocytopenia before mobilization, and four (12.9%) had previously failed mobilization. The median peripheral blood CD34 + cell concentration was 27 cells/µL, and the median total CD34 + cell yield was 4.3 × 10 6 /kg. A median of one apheresis procedure was required. Plerixafor was used in 12 patients (38.7%), and all 31 patients achieved successful collection. Febrile neutropenia occurred in seven patients (22.6%); red blood cell and platelet transfusions were required in 22.6% and 35.5%, respectively. Thirty patients (96.8%) proceeded to ASCT. Median neutrophil and platelet engraftment occurred on days 12 and 14, respectively. Conclusions BEGEV-based chemomobilization, with selective use of plerixafor, resulted in successful stem cell collection in all patients with HL or NHL, including those with a history of mobilization failure. Hematologic toxicity and supportive care requirements were not negligible, but almost all patients subsequently underwent ASCT and engraftment was satisfactory.